Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced its sponsorship with the American Association of Feline Practitioners (AAFP).

"The AAFP supports feline practitioners by providing tools, guidelines and resources to assist in delivering continuing, high-quality service to their cat patients" said Larry Heaton, Zomedica's Chief Executive Officer, "We are honored to partner with such an organization to provide a healthy future for the feline veterinary profession."

A leading organization in the field of feline medicine, "the AAFP works to improve the standards of feline health and wellbeing, in part by providing its members and the veterinary community with valuable feline resources." (AAFP website). The yearlong sponsorship will help the association support cat practitioners, most especially with their weekly Newsbrief, their annual AAFP conference and speaker sponsorship.

"The theme for this year's AAFP Annual Conference is Enriching Feline Care & the Veterinary Experience which will include a comprehensive, feline-specific, and high-level behavior and medical program," commented Heather O'Steen, CAE, AAFP's CEO. "We are excited to add Zomedica as a sponsor that shares the same passion to support and promote feline care."

Zomedica's product portfolio includes the TRUFORMA® in-clinic biosensor testing platform which offers the first and ONLY feline-optimized TSH assay capable of measuring TSH concentrations below levels appropriate for canine diagnoses. Zomedica also offers the PulseVet® system to treat cats with osteoarthritis using high-energy sound wave technology to provide proven, effective, and sedation-free healing.

About the American Association of Feline Practitioners

The American Association of Feline Practitioners (AAFP) supports its members and improves the health and welfare of cats by supporting high standards of practice, continuing education, and evidence-based medicine (catvets.com). As a trusted leader in the veterinary community, the AAFP has a long-standing reputation for facilitating high standards for feline care, including the creation of guidelines for practice excellence and educational resources. Over the years, the AAFP has encouraged veterinary professionals to continuously re-evaluate preconceived notions of practice strategies in an effort to advance the quality of feline medicine. Launched in 2012, the Cat Friendly Practice® (CFP) Program (catvets.com/cfp) was created to improve the treatment, handling, and overall healthcare provided to cats. Its purpose is to equip veterinary practices, teams, and individuals with tools and resources to reduce the stress associated with the veterinary visit and elevate the standard of care provided to cats. Launched in 2020, the Cat Friendly Certificate Program (catvets.com/certificate) now provides this education to individual veterinary professionals. Learn more about the AAFP's Annual Conference at www.catvets.com/conference2022.

About Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.

Follow Zomedica

• Email Alerts: http://investors.zomedica.com
• LinkedIn: https://www.linkedin.com/company/zomedica
• Facebook: https://m.facebook.com/zomedica
• Twitter: https://twitter.com/zomedica
• Instagram: https://www.instagram.com/zomedica_inc

Reader Advisory

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to American economic growth, demand for the Company's products, the Company's ability to produce and sell its products, our ability to successfully integrate and operate the PulseVet business, the sufficiency of our budgeted capital and operating expenditures, the cost, adequacy and availability of supplies required for our operations, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results, and financial condition.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate and operate the Pulse Vet business, uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty regarding the cost, adequacy and availability of supplies required for our operations; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations: risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:
PCG Advisory Group
Kirin Smith, President
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1.646.823.8656